Compound: disopyramide
SMILES: O=C(N)C(c1ncccc1)(c2ccccc2)CCN(C(C)C)C(C)C
InChIKey: UVTNFZQICZKOEM-UHFFFAOYSA-N
Synonyms: disopyramide, 3737-09-5, Dicorantil, Lispine, Disopiramida, Isorythm, Rythmodan P, Disopyramidum, Ritmilen, Dl-disopyramide, Searle-703, SC-7031, (rs)-disopyramide, gamma-Diisopropylamino-alpha-phenyl-alpha-(2-pyridyl)butyramide, GFO928U8MQ, DTXSID1045536, alpha-(2-(Diisopropylamino)ethyl)-alpha-phenyl-2-pyridineacetamide, H-3292, 2-Pyridineacetamide, alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-phenyl-, CHEBI:4657, DTXCID9025536, 2-Pyridineacetamide, alpha-(2-(diisopropylamino)ethyl)-alpha-phenyl-, 4-[bis(propan-2-yl)amino]-2-phenyl-2-(pyridin-2-yl)butanamide, ALPHA-[2-(DIISOPROPYLAMINO)ETHYL]-ALPHA-PHENYL-2-PYRIDINEACETAMIDE, Diisopyramide, Palpitine, Rythmilen, 4-(bis(propan-2-yl)amino)-2-phenyl-2-(pyridin-2-yl)butanamide, 4-(bis(propan-2-yl)amino)-2-phenyl-2-(pyridin-2-yl)butanimidic acid, 4-[bis(propan-2-yl)amino]-2-phenyl-2-(pyridin-2-yl)butanimidic acid, RefChem:56638, C01BA03, (2RS)-4-Bis(1-methylethyl)amino-2-phenyl-2-(pyridin-2-yl)butanamide, 223-110-2, Ritmodan, Searle 703, Disopyramidum [INN-Latin], Disopiramida [INN-Spanish], Disopyramide Free Base, Disopyramide-d5, SC 7031, MFCD00057366, alpha-Diisopropylaminoethyl-alpha-phenylpyridine-2-acetamide, 4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide, 4-DIISOPROPYLAMINO-2-PHENYL-2-(2-PYRIDYL)BUTYRAMIDE, H 3292, CHEMBL517, 4-(diisopropylamino)-2-phenyl-2-pyridin-2-ylbutanamide, NCGC00015358-18, 2-Pyridineacetamide, .alpha.-[2-[bis(1-methylethyl)amino]ethyl]-.alpha.-phenyl-, 4-(diisopropylamino)-2-phenyl-2-(2-pyridyl)butanamide, 4-(diisopropylamino)-2-phenyl-2-(pyridin-2-yl)butanamide, a-[2-(Diisopropylamino)ethyl]-a-phenyl-2-pyridineacetamide, CAS-3737-09-5, Rythmodan P (TN), Disopyramid, (+/-)-DISOPYRAMIDE, Disopy ramide, SR-01000003039, C21H29N3O, Disopyramide CRS, 2-PYRIDINEACETAMIDE, .ALPHA.-(2-(BIS(1-METHYLETHYL)AMINO)ETHYL)-.ALPHA.-PHENYL-, 3737-09-5 (free base), NCGC00016985-01, Prestwick_681, EINECS 223-110-2, Norpace (Salt/Mix), Spectrum_001008, Disopyramide (Standard), Prestwick0_000266, Prestwick1_000266, Prestwick2_000266, Prestwick3_000266, Spectrum2_001033, Spectrum3_000404, Spectrum4_000524, Spectrum5_000943, DISOPYRAMIDE [MI], DISOPYRAMIDE [INN], DISOPYRAMIDE [JAN], UNII-GFO928U8MQ, D 7644, DISOPYRAMIDE [USAN], DISOPYRAMIDE [VANDF], Lopac0_000402, Lopac0_000411, SCHEMBL16153, BSPBio_000112, BSPBio_001928, DISOPYRAMIDE [MART.], KBioGR_001127, KBioSS_001488, MLS002222242, DISOPYRAMIDE [WHO-DD], DivK1c_000489, SPBio_001245, SPBio_002331, BPBio1_000124, GTPL7167, orb1308993, SC 13957 (Salt/Mix), SCHEMBL23931452, KBio1_000489, KBio2_001488, KBio2_004056, KBio2_006624, KBio3_001148, Disopyramide (JP18/USAN/INN), NINDS_000489, GLXC-23503, HMS1568F14, HMS2095F14, HMS2234G08, HMS3261A06, HMS3369O21, HMS3712F14, HMS3886E08, HMS5084B10, DISOPYRAMIDE [EP MONOGRAPH], MSK14873, Disopyramide [USAN:INN:BAN:JAN], Disopyramide 1.0 mg/ml in Methanol, Tox21_110727, Tox21_500402, BDBM50028893, EBC-12812, HY-12533R, NSC791109, s5490, AKOS015894712, Tox21_110727_1, CCG-204495, DB00280, FD22542, LP00402, NSC-791109, SDCCGSBI-0050388.P006, IDI1_000489, NCGC00015358-04, NCGC00015358-05, NCGC00015358-06, NCGC00015358-08, NCGC00015358-09, NCGC00015358-10, NCGC00015358-11, NCGC00015358-12, NCGC00015358-13, NCGC00015358-14, NCGC00015358-15, NCGC00015358-19, NCGC00015358-24, NCGC00015358-25, NCGC00093829-01, NCGC00093829-02, NCGC00093829-03, NCGC00261087-01, AC-16018, BS-17145, DA-52588, HY-12533, SMR001307254, SY052319, SBI-0050388.P005, CAS: 3737-09-5, AB00053462, CS-0011990, D2793, EU-0100402, NS00003733, ST50411970, C06965, D00303, T70845, AB00053462_16, AB00053462_17, Q425120, SR-01000003039-3, |A-Diisopropylaminoethyl-|A-phenylpyridine-2-acetamide, 4-Diisopropylamino-2-phenyl-2-(2-pyridyl)-butyramide, BRD-A29734509-001-03-8, BRD-A29734509-011-02-9, BRD-A29734509-011-06-0, BRD-A29734509-011-12-8, BRD-A29734509-011-13-6, SR-01000003039-10, 4-(Diisopropylamino)-2-phenyl-2-(2-pyridinyl)butanamide, 4-(Diisopropylamino)-2-phenyl-2-(2-pyridyl)butyramide, Z1556052559, 4-(Diisopropylamino)-2-phenyl-2-(2-pyridinyl)butanamide #, 4-[bis(methylethyl)amino]-2-phenyl-2-(2-pyridyl)butanamide, 4-[Di(propan-2-yl)amino]-2-phenyl-2-(pyridin-2-yl)butanamide, 4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamideEE, Disopyramide, European Pharmacopoeia (EP) Reference Standard, a-[2-[Bis(1-methylethyl)amino]ethyl]-a-phenyl-2-pyridineacetamide, (2RS)-4-[bis(1- methylethyl)amino]-2-phenyl-2-(pyridin-2-yl)butanamide, .alpha.-(2-(Diisopropylamino)ethyl)-.alpha.-phenyl-2-pyridineacetamide, .gamma.-Diisopropylamino-.alpha.-phenyl-.alpha.-(2-pyridyl)butyramide, 2-Pyridineacetamide, .alpha.-[2-(diisopropylamino)ethyl]-.alpha.-phenyl-, alpha-[2-[Bis(1-methylethyl)amino]ethyl]-alpha-phenyl-2-pyridineacetamide, racemic 2-phenyl-2-(2-pyridyl)-4-[N,N-bis(1-methylethyl)amino]butanamide
Theoretical properties:
molecular_formula: C21H29N3O
molecular_weight: 339.5 g/mol
exact_mass: 339.231062557 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 3
rotatable_bond_count: 8
heavy_atom_count: 25
topological_polar_surface_area: 59.2 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
melting_point: 94.5-95 °C
Descriptions:
pubchem: Disopyramide is a monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug. It has a role as an anti-arrhythmia drug. It is a member of pyridines, a monocarboxylic acid amide and a tertiary amino compound.
chebi: A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a  anti-arrhythmia drug.
chembl: DISOPYRAMIDE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Disopyramide (INN, trade names Norpace and Rythmodan) is an antiarrhythmic medication used in the treatment of ventricular tachycardia. It is a sodium channel blocker and is classified as a Class 1a anti-arrhythmic agent. Disopyramide has a negative inotropic effect on the ventricular myocardium, significantly decreasing the contractility. Disopyramide also has general anticholinergic effects which contribute to unwanted adverse effects. Disopyramide is available in both oral and intravenous forms. In 1972, when it was one of the few alternatives to quinidine, it was praised for being more potent and somewhat less toxic. However, a 2012 review of antiarrhythmic drugs noted that disopyramide is among the most toxic agents, with a high burden of side effects and increased mortality (compared to placebo) when used to treat atrial fibrillation.